Bioplus Life Sciences

7-MX: For the Future of Every Child’s Vision

Theialife is a virtual, late-clinical-stage novel ophthalmology drug company founded on an unyielding commitment to develop innovative, breakthrough therapies for ophthalmological applications. Our mission is to prevent sight deterioration, restore vision, and enrich lives by advancing the current standard of care.

Research & Development

Bioplus Life Sciences is a research-driven company, continually evolving and aspires to improve products and service quality through the utilization of the latest technology combined with extensive research and experimentation on food ingredients and Nutraceutical products.

January 21, 2025

Bioplus chairman Sundeep Aurora shares his perspective on the impact of Trump 2.0 on the Indian Pharma industry & Bioplus' latest drug for pediatric myopia

November 23, 2023

Dr. Trier with Prof. Zeng, a renowned myopia researcher from China, at the EVER 2023 conference in València, Spain, October 26–28

At the EVER meeting in València, Spain, Dr. Klaus Trier was invited to talk at the myopia control session. Dr. Trier presented the latest analysis of data from 757 myopic children demonstrating high efficacy of 7‑MX.